证券代码：688163 证券简称：赛伦生物 公告编号：2025-028 上海赛伦生物技术股份有限公司 关于参加 2025 年上海辖区上市公司三季报集体业绩 说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络文字互动 投资者可于 2025 年 11 月 6 日（星期四）至 11 月 12 日（星期三）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 dmb@serum-china.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 上海赛伦生物技术股份有限公司（以下简称"公司"）已于 2025 年 10 月 28 日披露公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 11 月 13 日 （星期 四） ...

Core Viewpoint - Sairun Bio is a leading enterprise in the field of biotoxins and biosafety drugs in China, focusing on the research, development, production, and sales of related preventive and therapeutic drugs, with strong technical barriers [1] Group 1: Business Performance - For Q3 2025, Sairun Bio reported revenue of 175 million yuan, ranking 31st out of 34 in the industry, significantly lower than the top company, Changchun High-tech, which had 9.807 billion yuan, and the second, Kanghong Pharmaceutical, with 3.624 billion yuan [2] - The net profit for the same period was 64.21 million yuan, ranking 17th in the industry, far behind the leading company, Tonghua Dongbao, which reported 1.188 billion yuan, and Changchun High-tech at 1.06 billion yuan [2] Group 2: Financial Ratios - As of Q3 2025, Sairun Bio's debt-to-asset ratio was 3.14%, slightly up from 2.73% year-on-year, but significantly lower than the industry average of 26.88%, indicating strong solvency [3] - The gross profit margin for Q3 2025 was 78.43%, a slight decrease from 78.83% year-on-year, yet still above the industry average of 70.17%, reflecting strong profitability [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders for Sairun Bio decreased by 14.10% to 6,635, while the average number of circulating A-shares held per household increased by 183.92% to 16,300 [5]

Core Points - The company, Shanghai Sailun Biotechnology Co., Ltd., ensures the authenticity, accuracy, and completeness of the quarterly report, with all board members and senior management bearing legal responsibility for any misrepresentation or omissions [2][7] - The quarterly financial statements are not audited, indicating that the financial data may not have undergone a thorough external review [3][6] - The report includes a statement regarding non-recurring gains and losses, but it is noted that there are no significant changes in the financial indicators or major accounting data [4][5] Financial Data - The financial statements for the period ending September 30, 2025, are prepared in RMB and are unaudited [6][7] - The report mentions that there were no profits recorded from mergers under common control for the current or previous periods, with both showing a net profit of 0 yuan [6]

Core Insights - The company reported a revenue of 175,138,574.09 yuan for the first three quarters of 2025, representing a year-on-year growth of 1.07% [1] - The net profit attributable to shareholders of the listed company was 64,210,654.81 yuan, showing a year-on-year increase of 2.01% [1] Financial Performance - Revenue for the first three quarters of 2025: 175.14 million yuan [1] - Year-on-year revenue growth: 1.07% [1] - Net profit for the first three quarters of 2025: 64.21 million yuan [1] - Year-on-year net profit growth: 2.01% [1]

Core Insights - Sirun Biotech (688163.SH) reported a revenue of 175 million yuan for the first three quarters of 2025, reflecting a year-on-year growth of 1.07% [1] - The company's net profit attributable to shareholders reached 64.21 million yuan, marking a year-on-year increase of 2.01% [1] - The adjusted net profit was 56.44 million yuan, showing a year-on-year growth of 12.15% [1] - Basic earnings per share stood at 0.59 yuan [1]

Core Viewpoint - SAILUN Biotech (688163.SH) reported a slight increase in revenue and net profit for the first three quarters of 2025, indicating stable growth in its financial performance [1] Financial Performance - The total operating revenue for the first three quarters reached 175 million yuan, representing a year-on-year growth of 1.07% [1] - The net profit attributable to shareholders was 64.21 million yuan, showing a year-on-year increase of 2.01% [1] - The basic earnings per share stood at 0.59 yuan [1]

Financial Performance - The company's revenue for Q3 2025 was ¥74,319,211.31, a decrease of 1.22% compared to the same period last year[3] - The total profit for the period was ¥37,052,211.73, reflecting an increase of 1.30% year-over-year[3] - The net profit attributable to shareholders was ¥31,233,921.44, up by 1.94% from the previous year[3] - The net profit after deducting non-recurring gains and losses was ¥27,908,599.12, which increased by 1.43% compared to the same period last year[3] - The basic earnings per share for the quarter was ¥0.29, with a year-to-date figure of ¥0.59, reflecting a 1.72% increase[4] - Total operating revenue for the first three quarters of 2025 reached RMB 175,138,574.09, a slight increase from RMB 173,291,573.09 in the same period of 2024, representing a growth of approximately 1.06%[17] - Net profit for the first three quarters of 2025 was RMB 64,210,654.81, compared to RMB 62,947,540.75 in 2024, indicating an increase of approximately 2.00%[19] - The company’s total profit for the first three quarters of 2025 was RMB 74,817,469.40, compared to RMB 73,631,451.78 in 2024, reflecting an increase of approximately 1.61%[19] Assets and Liabilities - Total assets at the end of the period were ¥1,161,534,035.34, representing a 3.71% increase from the end of the previous year[4] - The company's total liabilities rose to CNY 36,453,171.78 from CNY 24,533,348.17, reflecting an increase in financial obligations[14] - The total equity attributable to shareholders increased to CNY 1,125,080,863.56 from CNY 1,095,500,608.75, showing growth in shareholder value[14] - The company's accounts receivable increased to CNY 65,179,876.60 from CNY 36,678,957.69, indicating improved sales performance[12] - The fixed assets increased to CNY 114,577,515.78 from CNY 108,979,777.03, suggesting ongoing investment in infrastructure[13] - The company reported a total non-current asset of CNY 244,024,044.52, up from CNY 203,671,011.22, reflecting long-term investment growth[13] Cash Flow and Liquidity - The company reported a net cash flow from operating activities of ¥38,166,287.22, which decreased by 6.89% year-to-date[3] - The company's cash and cash equivalents decreased to CNY 74,948,031.35 from CNY 182,107,137.22, indicating a significant reduction in liquidity[12] - Cash flow from operating activities generated a net amount of RMB 38,166,287.22 in 2025, down from RMB 40,989,386.86 in 2024, a decrease of about 6.93%[21] - Cash flow from investing activities resulted in a net outflow of RMB 110,427,075.57 in 2025, contrasting with a net inflow of RMB 53,086,071.07 in 2024[22] - Cash and cash equivalents at the end of the third quarter of 2025 totaled RMB 74,948,031.35, a decrease from RMB 210,364,165.68 at the end of the same period in 2024[23] Research and Development - Research and development expenses totaled ¥4,402,191.05, accounting for 5.92% of revenue, an increase of 0.91 percentage points[4] - The company incurred research and development expenses of RMB 12,878,600.46 in 2025, down from RMB 16,170,774.43 in 2024, a decrease of about 20.00%[18] Non-Recurring Items - Non-recurring gains and losses for the period amounted to ¥3,325,322.32, with a year-to-date total of ¥7,774,982.99[7] - The company reported other income of RMB 497,430.05 in 2025, significantly lower than RMB 3,549,290.77 in 2024, indicating a decline of approximately 86.00%[18] Inventory and Current Assets - The total current assets slightly increased to CNY 917,509,990.82 compared to CNY 916,362,945.70 in the previous period[12] - The company's inventory decreased to CNY 38,759,460.00 from CNY 43,275,462.94, which may indicate improved inventory management[12] Operating Costs - Total operating costs decreased to RMB 105,193,973.75 in 2025 from RMB 107,900,485.01 in 2024, reflecting a reduction of about 2.52%[18]

Core Viewpoint - The company reported a slight decline in revenue for the third quarter, while net profit showed a modest increase, indicating mixed performance in the latest financial results [1] Financial Performance - Q3 revenue was 74.3192 million yuan, a year-on-year decrease of 1.22% [1] - Q3 net profit was 31.2339 million yuan, a year-on-year increase of 1.94% [1] - Revenue for the first three quarters was 175 million yuan, a year-on-year increase of 1.07% [1] - Net profit for the first three quarters was 64.2107 million yuan, a year-on-year increase of 2.01% [1]

Group 1 - On September 25, 2023, Siron Biotech experienced a decline of 0.99% with a trading volume of 17.9856 million yuan [1] - The financing data for Siron Biotech on the same day showed a financing purchase amount of 1.4958 million yuan and a financing repayment of 2.0808 million yuan, resulting in a net financing buy of -0.5850 million yuan [1] - As of September 25, 2023, the total balance of margin trading for Siron Biotech was 155 million yuan, with the financing balance accounting for 6.19% of the circulating market value, indicating a high level compared to the past year [1] Group 2 - As of June 30, 2023, the number of shareholders for Siron Biotech was 7,724, an increase of 9.39% from the previous period, while the average circulating shares per person decreased by 8.58% to 5,744 shares [2] - For the first half of 2023, Siron Biotech reported an operating income of 101 million yuan, representing a year-on-year growth of 2.82%, and a net profit attributable to shareholders of 32.9767 million yuan, up 2.07% year-on-year [2] - Since its A-share listing, Siron Biotech has distributed a total of 248 million yuan in dividends, with 150 million yuan distributed over the past three years [2]

Group 1 - The company, Sairun Biotech (688163.SH), has stated that it currently has no plans to export its anti-snake venom serum [1]